TMCnet News
Research and Markets: Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors Pipeline Insights Review 2015Research and Markets (http://www.researchandmarkets.com/research/wpnp5n/poly_adpribose) has announced the addition of the "Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors -Pipeline Insights" report to their offering. Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors - Pipeline Insights provides the in-depth analysis of the pipeline assets across the Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. Poly (ADP-Ribose) Polymerase 2 (PARP-2)Inhibitors - Pipeline Insights Report covers the Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors. Scope - The report provides a Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery. - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit http://www.researchandmarkets.com/research/wpnp5n/poly_adpribose
View source version on businesswire.com: http://www.businesswire.com/news/home/20150828005603/en/ |